Formulation and Assessment of Lipid-based Nanoformulation of Luliconazole

Abstract

The luliconazole preformulation study aimed to determine the best way to administer medicine using SNEDDS. The plain white powder, luciconazole, showed a number of different crystal structures and was very soluble in isopropyl myristate and oleic acid, as confirmed through partition coefficients in n-octanol. With a robust linear standard curve at 295 nm, UV spectroscopy verified its dependability for analysis. Luliconazole and the necessary excipients for SNEDDS formulation were found to be compatible according to fourier-transform infrared spectroscopy (FTIR) spectra. Using a 32-factorial design enhanced the efficacy and stability of SN-7 batches, especially when diluted with water. Thermal studies revealed formulation dynamics-critical thermal behaviors and crystalline structures (DSC and XRD). The end SNEDDS showed a strong suppression of Candida albicans growth and a higher viscosity, allowing for longer surface retention. Ethical approval facilitated comparative evaluations against a commercial formulation. High-performance liquid chromatography (HPLC) analysis validated SN-7’s purity, enabling a benchmark for monitoring luliconazole plasma concentrations post-application and ex-vivo permeation studies, vital for potential fungal infection treatments. A rigorous three-month stability study affirmed SN-7’s unwavering properties across diverse environmental conditions, ensuring sustained effectiveness. An IEAC-approved skin irritation study on albino wistar rats endorsed SN-7’s minimal irritancy, underscoring its safety and comfort, which is pivotal for pharmaceutical acceptance in topical drug delivery.